)
Wave Life Sciences (WVE) investor relations material
Wave Life Sciences R&D Day 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline overview and program updates
WVE-008 is a GalNAc-conjugated RNA editing candidate designed to correct the PNPLA3 I148M mutation and restore normal PNPLA3 function.
WVE-007 is an INHBE siRNA in Phase II; plans include a maintenance trial and 600 mg INLIGHT cohort data, with durable suppression supporting potential once- or twice-yearly dosing.
SpiNA and PN conjugates aim to extend RNAi activity and deliver medicines to extrahepatic tissues, including adipose and kidney.
Bifunctional oligonucleotides combine silencing, editing, or upregulation of distinct RNA targets in one construct.
Clinical trial data and development milestones
WVE-008 preclinical studies showed potent, specific editing, reduced hepatocyte fat, distribution across liver zones, and over 60% editing in mouse hepatic stellate cells.
The WVE-008 clinical candidate achieved up to 85% hepatocyte editing; the program aims to edit at least 50% of PNPLA3 transcripts.
A single 240 mg WVE-007 dose was associated at six months with placebo-adjusted visceral fat reduction of 14%, waist reduction of 3%, and lean-mass stabilization of 2%; Activin E suppression lasted at least seven months.
The first-in-human WVE-008 study is planned to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in homozygous carriers; WVE-007 Phase 2a multidose INLIGHT is enrolling people with higher baseline adiposity and comorbidities.
Preclinical PN-conjugate/SpiNA data showed 75% SOD1 mRNA knockdown and sustained 50% knockdown up to three months after one dose.
R&D strategy and innovation priorities
The Oligonucleotide Center of Excellence and PRISM platform integrate human genetics, modality selection, rational design, predictive models, manufacturing, and cross-program learning.
SpiNA GalNAc-siRNAs showed over 10-fold greater AGO2 loading than reference siRNAs; one dose produced durable PCSK9 reduction through at least day 56.
PN conjugate chemistry is being tuned for tissue-specific delivery without LNPs or other delivery agents; preclinical constructs achieved up to 90% adipose knockdown, and a kidney-directed variant reduced SOD1 mRNA 75% in mice.
Bifunctional designs demonstrated simultaneous target silencing and RNA editing or upregulation; LPA-PCSK9 SpiNA lowered both targets, and a silencing/upregulation construct achieved over fivefold target Y upregulation in vivo.
- Pipeline milestones advanced with $431M in cash and runway into Q3 2028.WVE
Q3 2026 - INHBE pairs durable fat-loss potential with lean-mass preservation; AAT editing advances toward registration.WVE
Chardan's 10th Annual Healthcare Conference - Shareholders face director, auditor, pay, and 11M-share plan votes after redomiciliation.WVE
Proxy filing - Durable RNA editing and innovative obesity trials drive clinical and regulatory progress in 2024.WVE
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advancing RNAi and RNA editing therapies with durable efficacy and infrequent dosing.WVE
Corporate presentation - INHBE and WVE-006 advance with strong clinical data, regulatory momentum, and strategic interest.WVE
Canaccord Genuity's 46th Annual Growth Conference - WVE-007 and AATD programs are set for major clinical and regulatory milestones in the coming year.WVE
Bank of America SMID Cap Virtual Conference - Q2 2026 revenue dropped, net loss widened, but pipeline progress and cash runway remain strong.WVE
Q2 2026 - Durable fat loss and muscle preservation with WVE-007, plus key milestones in 2024 and 2026.WVE
44th Annual J.P. Morgan Healthcare Conference
Next Wave Life Sciences earnings date
Next Wave Life Sciences earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)